PDF
NACI Recommendations on the use of Medicago COVID-19 vaccine (Covifenz)
Organization: Public Health Agency of Canada (PHAC)Published: 2022
"The Medicago COVID-19 vaccine (Covifenz) is the first virus-like particle (VLP) COVID-19 vaccine authorized in Canada. Medicago Covifenz was authorized for use in adults 18-64 years of age by Health Canada on February 24, 2022." - NACI Recommendations on the use of Medicago COVID-19 vaccine (Covifenz)
Additional Authors: Shainoor J. Ismail, Kelsey Young, Matthew C Tunis, Beate Sander, and Robyn Harrison
Resource Group:
Implementation Tool
Product Type: Guide
Vaccine Safety
Sub Topics: Vaccine Safety and Development
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Program Planning and Delivery
Program Delivery and Evaluation
Clinics
Vaccine Management
Allocation and Distribution
Storage and Handling
Product Type: Guide
Category:
Vaccine Safety and Development,Vaccine Safety,Sub Topics: Vaccine Safety and Development,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19,Program Planning and Delivery,Program Delivery and Evaluation,Clinics,Vaccine Management,Allocation and Distribution,Storage and Handling Vaccine Safety and DevelopmentVaccine Safety
Sub Topics: Vaccine Safety and Development
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Program Planning and Delivery
Program Delivery and Evaluation
Clinics
Vaccine Management
Allocation and Distribution
Storage and Handling
Language:
English
Link
AudioResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.